Nebivolol 300 mg (5 mg / 60 capsules)
$39.95
Nebivolol is a third-generation β-adrenoceptor blocker with high β1-selectivity and a unique secondary mechanism: activation of endothelial nitric oxide synthase (eNOS) via GRK/β-arrestin biased agonism, producing vasodilation absent from earlier-generation β-blockers. Research applications include β1-AR pharmacology,… CAS: 99200-09-06 | Formula: C22H25F2NO4 | Content: 300 mg (5 mg per capsule) | Research use only | Third-party lab tested.
Buy Nebivolol 300 mg (5 mg / 60 capsules) – Swiss Chems USA
Nebivolol 300 mg (5 mg / 60 capsules) — Research Overview
Nebivolol is a third-generation β-adrenoceptor blocker with high β1-selectivity and a unique secondary mechanism: activation of endothelial nitric oxide synthase (eNOS) via GRK/β-arrestin biased agonism, producing vasodilation absent from earlier-generation β-blockers. Research applications include β1-AR pharmacology, biased agonism at β-adrenoceptors, eNOS activation pathway investigation, and NO-mediated vascular biology research.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Intended use: This material is supplied for laboratory and in-vitro research only. It is not a drug, food, or cosmetic and is not intended for human or animal consumption.
Nebivolol 300 mg (5 mg / 60 capsules) Chemical Properties
| Property | Specification |
|---|---|
| Chemical Formula | C22H25F2NO4 |
| Synonyms | Bystolic (trade name), Nebilet (trade name), Nebivololum |
| Molar Mass | 405.44 g/mol |
| CAS Number | 99200-09-06 |
| PubChem CID | 71301 |
| Total Compound Content | 300 mg (5 mg per capsule) |
| Shelf Life | 36 months |
Nebivolol 300 mg (5 mg / 60 capsules) Research Applications
Nebivolol is a difluoro-chroman-based β1-selective adrenoceptor antagonist with approximately 290-fold selectivity for β1 over β2-AR. What distinguishes nebivolol pharmacologically from earlier β-blockers is its concurrent eNOS activation via a GRK2/β-arrestin biased signalling pathway at β2-AR — a G protein-independent mechanism that activates eNOS/NO/cGMP vasodilation independent of Gsα. This biased agonism at β2-AR (producing vasodilation) combined with β1-AR antagonism (reducing cardiac output) creates a haemodynamic profile that differentiates nebivolol from carvedilol, metoprolol, and atenolol. Nebivolol is a racemate — the SRRR enantiomer is primarily responsible for β1 antagonism, while the RSSS enantiomer potentiates antihypertensive effects via eNOS pathway. CYP2D6 polymorphisms significantly affect nebivolol metabolism, with poor metabolisers having substantially higher plasma exposure — an important variable in pharmacogenomic research designs. Half-life 12–19 hours. Supplied in 5 mg capsules. Independently third-party HPLC-tested; COA available per batch.
Nebivolol 300 mg (5 mg / 60 capsules) Frequently Asked Questions
What is the GRK/β-arrestin biased agonism mechanism that distinguishes nebivolol from other β-blockers?
Most β-blockers are Gα antagonists — they block Gsα-coupled cAMP signalling at β-ARs without activating alternative pathways. Nebivolol is also a GRK2/β-arrestin biased agonist at β2-AR: it activates GRK2-mediated receptor phosphorylation and β-arrestin recruitment without activating Gsα. β-arrestin then scaffolds EGFR transactivation and ERK1/2 phosphorylation cascades that activate eNOS and promote NO production. This G protein-independent, β-arrestin-dependent signalling produces vasodilation that is absent from pure Gα-antagonist β-blockers. This biased agonism mechanism is also documented for carvedilol and represents an active area of β-AR pharmacology research.
How does nebivolol’s eNOS activation differ mechanistically from direct NO donors in vascular research?
Direct NO donors (nitroprusside, SNAP, DETA-NONOate) deliver exogenous NO or spontaneously release it, bypassing eNOS entirely. Nebivolol activates endogenous eNOS via β-arrestin/EGFR/Akt signalling, producing NO through the physiological L-arginine/NOS pathway in vascular endothelial cells. This eNOS-dependent NO production is subject to normal substrate availability, NOS regulation, and shear stress modulation — making nebivolol relevant to studies examining endogenous NO pathway activation versus exogenous NO supplementation. The eNOS pathway activation also produces BH4-dependent effects on NOS coupling that differ from uncoupled exogenous NO delivery.
How do CYP2D6 polymorphisms affect nebivolol pharmacokinetics in research studies?
Nebivolol is predominantly metabolised by CYP2D6 via hydroxylation and glucuronidation. CYP2D6 poor metabolisers (approximately 7–10% of Caucasian populations, 2% of Asians) have significantly higher nebivolol plasma exposure and longer effective half-life compared to extensive metabolisers. In pharmacogenomic research designs, CYP2D6 genotyping of experimental subjects is important for interpreting interindividual variation in nebivolol PK/PD relationships. This CYP2D6 dependence is shared by several β-blockers (metoprolol, carvedilol) but not others (atenolol, bisoprolol), making nebivolol useful in comparative CYP2D6-dependent versus independent β-blocker metabolism studies.
Research Use Disclaimer
All product information is provided for educational and laboratory research reference only. Any form of introduction into humans or animals is prohibited. Handle only in licensed research settings in accordance with applicable laws and institutional protocols.
| Weight | 3 lbs |
|---|
Related products
BPC-157 with Arginine Salt
Price range: $39.99 through $599.50
Reviews
There are no reviews yet.